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AbstrAct
Introduction The global prevalence of obesity has 
risen significantly in recent decades. There is a 
pressing need to identify effective interventions to treat 
established obesity that can be delivered at scale. The 
aim of the Doctor Referral of Overweight People to a 
Low-Energy Treatment (DROPLET) study is to determine 
the clinical effectiveness, feasibility and acceptability 
of referral to a low-energy total diet replacement 
programme compared with usual weight management 
interventions in primary care.
Methods and analysis The DROPLET trial is a 
randomised controlled trial comparing a low-energy 
total diet replacement programme with usual weight 
management interventions delivered in primary care. 
Eligible patients will be recruited through primary care 
registers and randomised to receive a behavioural 
support programme delivered by their practice nurse 
or a referral to a commercial provider offering an 
initial 810 kcal/d low-energy total diet replacement 
programme for 8 weeks, followed by gradual food 
reintroduction, along with weekly behavioural support 
for 24 weeks. The primary outcome is weight change at 
12 months. The secondary outcomes are weight change 
at 3 and 6 months, the proportion of participants 
achieving 5% and 10% weight loss at 12 months, and 
change in fat mass, haemoglobin A1c, low-density 
lipoprotein cholesterol and systolic and diastolic blood 
pressure at 12 months. Data will be analysed on the 
basis of intention to treat. Qualitative interviews on 
a subsample of patients and healthcare providers 
will assess their experiences of the weight loss 
programmes and identify factors affecting acceptability 
and adherence.
Ethics and dissemination This study has been 
reviewed and approved by the National Health 
ServiceHealth Research Authority (HRA)Research 
Ethics Committee (Ref: SC/15/0337). The trial 
findings will be disseminated to academic and health 
professionals through presentations at meetings and 
peer-reviewed journals and to the public through the 
media. If the intervention is effective, the results will be 
communicated to policymakers and commissioners of 
weight management services.
trial registration number ISRCTN75092026.
IntroductIon
The prevalence of obesity worldwide has 
more than doubled since 1980.1 According 
to the latest estimates from the WHO, more 
than 1.9 billion adults were overweight, of 
whom 600 million were obese, representing 
39% and 13% of the world’s adult popula-
tion, respectively.2 Obesity is associated with 
premature mortality,3 but also substantial 
morbidity, including significantly increased 
risks of diabetes, cardiovascular disease and 
most non-smoking-related cancers, as well as 
physical impairments linked to excess weight 
such as breathlessness, joint problems and 
back pain.4 Collectively this creates a burden 
of ill-health and reduced quality of life for 
individuals, additional treatment costs to 
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Protocol
strengths and limitations of this study
 ► This study is the largest randomised controlled 
trial to date of a low-energy total diet replacement 
programme for weight management in routine 
primary care.
 ► This intervention is based on a model of care where 
general practitioners refer patients to a programme 
delivered in the community by a commercial 
provider using non-National Health Service staff, 
which, if successful, could be readily adopted into 
practice without the need for specialist training for 
the primary care workforce.
 ► The primary outcome is weight at 1 year. Although 
this is 9 months after the low-energy total diet 
replacement, epidemiological evidence suggests 
that any weight lost will continue to be regained 
beyond 1 year.
 ► The intention of obesity treatment programmes is to 
improve long-term health, but this study does not 
include morbidity or mortality outcomes.
 ► Longer term follow-up data would be helpful to 
better estimate the longer health impact and cost-
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the National Health Service (NHS) and reductions in 
economic productivity.5 While high priority must be 
given to prevent future cases of obesity, in the short term, 
there is a pressing need to identify effective interven-
tions to treat established obesity. Research has shown that 
even modest reductions in weight can bring significantly 
reduced risks of disease. For example, in the US Diabetes 
Prevention Program (DPP), individuals randomised to 
an intensive lifestyle intervention lost 7 kg by the end of 
the first year. Although some of this weight was regained, 
the intensive lifestyle group remained 4 kg lighter than 
the usual care group at 4 years, and this reduced the inci-
dence of diabetes by 58% relative to usual care,6 with 
benefits persisting to at least 15-year follow-up despite 
weight regain.7
Primary care is an important setting for weight manage-
ment interventions to reduce multimorbidity. However, 
although a number of interventions have been shown 
to be effective in intensive research studies, this success 
has not always been replicated in routine settings. For 
example, there was no significant reduction in weight 
when a weight loss programme adapted from the DPP 
was delivered by primary care teams.8 Our recent review 
of interventions suitable for use in routine care9 and a 
second review, using slightly different inclusion criteria, 
of interventions specifically delivered in primary care10 
both concluded that behavioural weight management 
interventions led by primary care practitioners were 
ineffective. This may relate in part to the complexity of 
advice needed for successful dietary change and the need 
for frequent contact to provide support, which exceeds 
the capacity of routine primary care systems. However, 
although a number of interventions have been shown to 
be effective in intensive research studies, this success has 
not always been replicated in routine settings. General 
practitioner (GP) referral to a commercial provider 
offering group-based support is an effective option for 
weight management in primary care, and our meta-anal-
ysis showed a mean reduction in weight of 2.3 kg over no 
intervention at 1 year.9 However, greater weight losses 
would be expected to bring greater health gains.
Very low-energy diets (VLEDs) have been used for 
weight loss over many years in specialist settings. A VLED 
is defined as a diet providing ≤800 kcal a day, based on 
the use of specially formulated products designed as 
the sole source of nutrition during periods of total diet 
replacement. When used as directed, these formula 
products meet 100% of the dietary reference values 
for vitamins, minerals and trace elements for healthy, 
weight-stable people and are enriched with high biolog-
ical-value protein. Although most contain some dietary 
fibre, a fibre supplement may also be recommended. A 
recent systematic review and meta-analysis of the available 
randomised controlled trials showed that behavioural 
weight management interventions incorporating a VLED 
led to 3.9 kg greater weight loss at 1 year compared with 
intensive specialist-delivered behavioural programmes.11 
However, most of the trials included in this review were 
small, typically including only 50–100 participants who 
were treated by obesity specialists, and many trials had 
methodological limitations.
UK guidance from the National Institute for Health and 
Care Excellence (NICE) recommends that VLEDs may 
only be used for a maximum of 12 weeks in people who 
have a clinical need to lose weight rapidly, such as prior 
to a knee replacement surgery or those seeking fertility 
services, but recommends against their routine use to 
manage obesity.12 Clinical guidance in the USA does not 
recommend the routine use of VLEDs, but rather suggests 
that their use ‘may be reasonable in limited circum-
stances, but only when provided by trained practitioners 
in a medical care setting where medical monitoring and 
high intensity lifestyle intervention can be provided’.13
Nevertheless, there has been growing interest in the 
potential for routine use of weight loss programmes 
similar to traditional VLEDs, in so far as they incorpo-
rate a period of total diet replacement using specially 
formulated products as the sole source of nutrition, 
but where the energy content is more than 800 kcal/
day but less than 1200 kcal/day. The NICE guidelines 
suggest that this type of low-energy diet could be consid-
ered for weight management, providing care is taken to 
ensure they are nutritionally complete.12 There is one 
observational report (n=91) on the use of these low-en-
ergy total diet replacement programmes in primary 
care which found that 64% of participants completed 
the 810 kcal/day dietary programme, defined as either 
12 weeks or reaching 20 kg weight loss, with a mean 
weight loss of 16.9 kg (SD=6.0 kg). One-third of partici-
pants starting the programme maintained a weight loss 
of ≥15 kg at 12 months.14 A large randomised controlled 
trial, the DiRECT (Diabetes Remission Clinical Trial) 
study, is currently underway to investigate whether this 
type of low-energy total diet replacement programme 
can be used to treat type 2 diabetes among people who 
are also overweight.15 It will compare the health effects 
of the current best-available type 2 diabetes care with 
those achieved through weight management based on 
a low-energy total diet replacement programme. While 
this will provide important mechanistic evidence on the 
links between weight loss and diabetes risk, it will be deliv-
ered by NHS staff, whereas the present study will test the 
effectiveness of referral outside the NHS to a commercial 
provider.
To fill this evidence gap, we will conduct a randomised 
controlled trial to specifically test the effectiveness of a 
GP referral to a community-based low-energy total diet 
replacement programme for patients who are obese 
and likely to benefit from weight loss. It will assess the 
clinical effectiveness of a weight loss intervention by 
measuring weight loss and the change in biomarkers of 
cardiovascular risk at 12 months relative to weight loss 
advice provided by practice nurses. This comparator is 
intended to represent ‘usual care’, although in practice 
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The context for this trial follows the established model 
for GP referral to community group-based weight loss 
programmes.16 This uses the generic authority and cred-
ibility of health professionals to motivate patients to 
consider weight management and the specialist knowl-
edge of the commercial provider to guide the intervention 
and offer frequent contact and behavioural support to 
the patient. If successful, it will provide another option 
for weight management that can be offered to patients 
in primary care, and GPs will be able to guide patients 
towards the treatment that best fits their circumstances 
and preferences. This trial will specifically test whether 
a partnership between GPs and providers will allow for 
the safe provision of low-energy total diet replacement 
programmes even for patients with multimorbidity who 
may gain the greatest benefits from such interventions 
but who may also need clinical oversight and adjust-
ments to some of their medications as they lose weight. 
It will provide the opportunity for qualitative research to 
investigate the perspectives of patients and healthcare 
practitioners on this type of treatment.
objective
The aim of the Doctor Referral of Overweight People to a 
Low-Energy Treatment (DROPLET) trial is to determine 
the clinical effectiveness, feasibility and acceptability of 
referral to a low-energy total diet replacement programme 




The study will take place in general practices in England. 
The study is designed as an individually randomised, 
two-arm and parallel group superiority trial with the 
primary endpoint as objectively measured changes in 
body weight from baseline to 12 months. Due to the 
nature of the intervention, it will not be possible to blind 
participants, clinicians or some of the study team to the 
treatment allocation after randomisation.
recruitment
Around 10 general practices will be identified to take part 
through the clinical research networks. Recruited prac-
tices will be asked to conduct a search of their electronic 
health records in order to identify suitable patients for 
the DROPLET study. As a result of this search, eligible 
patients will be sent an invitation letter from their GP as 
part of a staggered mailout. Patients will be encouraged 
to call the research team if they are interested in taking 
part.
GPs may also identify eligible patients during routine 
consultations. The GP will provide the patient with an 
invitation letter and suggest that the patient ring the study 
team. The study team will provide the potential partici-
pants with information on what taking part in the study 
will entail, and an initial assessment of suitability to take 
part. Those who make contact and self-report meeting 
the eligibility criteria will be scheduled for a baseline/
enrolment appointment.
Inclusion criteria
 ► participant is willing and able to give informed con-
sent for participation in the study
 ► aged 18 years or above
 ► body mass index (BMI) ≥30 kg/m2
 ► likely to benefit from weight loss in the GP’s opinion.
Exclusion criteria
 ► unable to understand English
 ► currently or recently (within 3 months of study entry) 
attended a weight management programme or cur-
rently participating in another weight loss study
 ► had bariatric surgery or scheduled bariatric surgery
 ► pregnant, breast feeding or planning to become preg-
nant during the course of the study
 ► receiving insulin therapy
 ► heart attack or stroke within the last 3 months
 ► heart failure of grade II New York Heart Association 
and more severe
 ► angina, arrhythmia, including atrial fibrillation or 
prolonged QT syndrome
 ► taking monoamine- oxidase inhibitor (MAOI) medi-
cation
 ► taking anticoagulant medication (eg, warfarin)
 ► taking varenicline (smoking cessation medication)
 ► chronic renal failure of stage 4 or 5
 ► active liver disease (except non-alcoholic fatty liver 
disease (NAFLD), a history of hepatoma or within 6 
months of onset of acute hepatitis
 ► people having active treatment for cancer other than 
skin cancer treated with curative intent by local treat-
ment only, or people taking hormonal or other long-
term secondary prevention treatment after initial can-
cer treatment
 ► active treatment or investigation for possible or con-
firmed gastric or duodenal ulcer; maintenance treat-
ment with acid suppression is not a contraindication
 ► porphyria
 ► scheduled for surgery within 12 months
 ► a member of household is already enrolled in the 
study
 ► unwilling to provide blood samples
 ► patients that the GP judges not able to meet the de-
mands of either treatment programme or measure-
ment schedule; this may include severe medical prob-
lems not listed above or severe psychiatric problems 
including substance misuse that make following the 
treatment programme or adhering to the protocol 
unlikely.
Participant flow
The baseline/eligibility assessment will be scheduled with 
a practice nurse or healthcare assistant at their own GP 
practice, where informed consent for participation in the 
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assessed. After demographic information and all base-
line measurements have been collected, the participant 
will be randomised to the allocated treatment group 
using the online randomisation system. The patients’ 
own GP will be notified by letter of the enrolment and 
randomisation of their patient, so that it may be docu-
mented on their medical record. Participants allocated 
to the low-energy total diet replacement programme and 
taking medications for type 2 diabetes, hypertension or 
high cholesterol will have their medications reviewed by a 
prescribing member of the clinical care team, usually the 
GP or trained nurse prescriber. During this medication 
review, the clinician will decide what changes to medica-
tions are required at the time the participant commences 
the low-energy total diet replacement programme, with 
guidance provided by the study team (see online supple-
mentary figure 1). In addition, participants randomised 
to the low-energy total diet replacement group and who 
take antihypertensive medications will be provided with a 
home blood pressure monitor and asked to record blood 
pressure once daily during the weight loss phase (weeks 
1–12). These readings can be used to guide clinicians 
with any further changes in hypertension medications.
All participants will be invited to attend a 4-week 
follow-up appointment with the practice nurse. The 
main purpose of the visit is a clinical review of medica-
tion, including any adjustments required. Any changes in 
medication will be recorded on the concomitant medi-
cation log. Participants will be invited to attend further 
follow-up visits with a member of the trial team at the GP 
practice at 12 weeks, 6 months and 12 month following 
randomisation. Participant flow through the study is 
outlined in figure 1.
sample size
The total number of participants to be recruited for this 
study is 270. This is based on a sample size calculation 
for the primary outcome using equal variance indepen-
dent samples t-test assuming a difference between groups 
at 12 months of 4 kg with an SD in both groups of 9 kg, 
obtained from a meta-analysis of published studies.11 The 
sample size has been inflated by 20% to account for attri-
tion, and assumes 90% power and two-sided alpha of 5%.
randomisation
All eligible, consenting participants will be randomised 
with an allocation ratio of 1:1 to low-energy total diet 
replacement or usual care programmes using an online 
programme, which reveals group allocation as per a 
computer-generated randomisation list. The rando-
misation criteria will be validated by an independent 
statistician. Allocation will be stratified by GP practice and 
baseline BMI (≤35 kg/m2 or >35 kg/m2) using stratified 
block randomisation with randomly varying block sizes 
of 2, 4 and 6. The randomisation software ensures full 
allocation concealment, with the allocation group only 
revealed to the person performing the randomisation 
once a study identifier and required stratification details 
have been entered.
Interventions
Low-energy total diet replacement
The programme offered to participants randomised to 
the active intervention will be provided by Cambridge 
Weight Plan, Northants, UK.
Following randomisation participants allocated to this 
group will be referred to a local Cambridge Weight Plan 
counsellor who will invite the participant to attend regular 
appointments for 24 weeks. These appointments consist 
of motivational support, encouragement, reassurance and 
problem-solving. All counsellors attend a 1-day in-person 
training course covering screening for suitability, nutri-
tion, behavioural approaches and medical monitoring. 
They must pass an accreditation examination before they 
are allowed to deliver the programme in the community. 
Thereafter, they have a yearly training updates, a nomi-
nated sponsor (experienced counsellor) and access to 
an online chat forum for sharing queries. Cambridge 
Weight Plan has a healthcare professional available for 
the counsellors to consult for advice on specific medical 
and nutritional queries. Counsellors delivering the inter-
vention for the purposes of this trial received short trial 
specific training before being allocated study participants.
During the first 12 weeks the participant will meet with 
their counsellor weekly. Patients will be asked to follow 
a programme based on using formula meal replacement 
products (soups, shakes and bars) and milk comprising 
810 kcal/day (3389 kJ/day). For the first 8 weeks, patients 
will be advised to replace all their usual foods and 
drinks with four of the formula products daily: 750 mL 
of skimmed milk, 2.25 L of water or other non-calorific 
drinks and a fibre supplement (total diet replacement 
stage). During the first 2 weeks, the formula products 
will be limited to liquid products (soups and shakes), 
but from week 3 onwards participants will have the 
option to include meal replacement bars as part of the 
formula product allowance. After 8 weeks there will be 
a 4-week stepwise reduction in the use of formula meal 
replacement products and a gradual reintroduction of 
food-based meals. The weight maintenance phase from 
week 12 to 24 participants attend monthly appointments 
at 16, 20 and 24 weeks, during this phase participants are 
advised to consume only one formula product a day, with 
the remainder of the diet to consist   of self-selected food. 
This weight maintenance phase will include a recom-
mendation to return to the total diet replacement stage 
for periods of up to 4 weeks if participants regain 1 kg or 
more than their weight measured at 12 weeks.
All consultations with counsellors and formula prod-
ucts will be provided to participants by their nominated 
counsellor and will be free of charge for the first 24 weeks, 
after which the intervention will end. Participants in both 
groups will be free to choose whether or not to continue 
with the programme, but at their own cost.
Comparator
The comparator intervention will consist of the usual 
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Figure 2 Schedule of measurements.18
of the practice nurse team who has been trained to 
offer a weight loss programme. The trial will take place 
only in practices where this is routine care. Participants 
allocated to the usual care group will not be prevented 
from attending other weight management groups if they 
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will be offered during the trial. The practice nurse will 
give participants a copy of the booklet ‘So you want to 
lose weight … for good’.17 This 47-page booklet provides 
advice akin to a behavioural weight management 
programme. The aim is to produce a weight loss goal of 
0.5–1 kg/week. It includes goal setting, advice on portion 
control and physical activity, other behavioural strate-
gies, and monitoring and feedback on progress. Nurses 
will be asked to offer a programme for 12 weeks, at a 
frequency that is usually used in the practice (eg, weekly 
or biweekly).
Physical activity
We recognise the importance of the role of aerobic 
and resistance exercise in facilitating weight loss and 
maintaining lean body mass to facilitate weight loss main-
tenance.
Participants randomised to the low-energy total diet 
replacement arm are given appropriate advice based on 
their previous exercise history, current ability and what is 
appropriate for their stage weight loss programme. Clin-
ical guidelines in the UK emphasise the importance of 
advice to increase physical activity, and we would expect 




 ► change in body weight from baseline to 12 months.
Secondary outcomes
 ► change in body weight from baseline at 3 and 6 
months
 ► proportion of participants achieving 5% and 
10% weight loss at 12 months
 ► change in fat mass between baseline and 12 months
 ► change in low-density lipoprotein (LDL) cholesterol 
concentrations between baseline and 12 months
 ► change in haemoglobin A1c (HbA1c) between base-
line and 12 months
 ► change in systolic and diastolic blood pressure be-
tween baseline and 12 months.
Exploratory outcomes
 ► change in fat mass from baseline to 12 weeks and from 
baseline to 6 months
 ► change in waist circumference from baseline to 3, 6 
and 12 months
 ► change in triglyceride and high-density lipopro-
tein (HDL) cholesterol concentrations between base-
line and 12 months
 ► change in fasting glucose and insulin concentra-
tions and change in Homeostatic Model Assesment 
(HOMA)of insulin resistance (HOMA- IR), insulin 
sensitivity (HOMA-%S) and beta cell function (HO-
MA-%B) between baseline and 12 months
 ► change in systolic and diastolic blood pressure be-
tween baseline and 3 months and between baseline 
and 6 months
 ► change in QRISK between baseline and 12 months
 ► change in the quality of Life measured using the EQ-
5D scale between baseline and 12 months
 ► change in obesity-related quality of life measured with 
the Obesity-Specific Quality of Life (OWLQOL) be-
tween baseline, 3, 6 and 12 months
 ► proportion of people continuing their weight loss at-
tempt and following the prescribed programme at 4, 
8 and 12 weeks
 ► the number of weight control behaviours that partic-
ipants are using assessed using the Oxford Food and 
Activity Behaviours (OxFAB) questionnaire18 at 3 and 
6 months
 ► qualitative interviews with a subsample of participants 
at 6 and 12 months
 ► adverse event (AE) reports up to 12 weeks, the end 
of the weight loss intervention or 6 months for AEs 
known or presumed to be related to gallstones.
Measurements
Figure 2 provides a summary of the measurements 
collected.
Sociodemographic characteristics
Participants will be asked to self-report age, sex 
and ethnicity.
Medical history
Relevant medical history and all concomitant medication 
will be recorded and checked against the participants’ 
medical record. Participants will also be asked to self-re-
port items required to determine cardiovascular risk 
score using QRISK2.19
Physical measurements
Height will be measured to the nearest 1 cm using stadi-
ometers available in the practice. Weight will be recorded 
to the nearest 0.1 kg using an electronic scale (SC-240 
MA, Tanita Japan), which will also record the proportion 
of body fat using bioelectrical impedance. Waist circum-
ference will be measured in the horizontal plane at the 
upper border of the iliac crest at the end of expiration20 
using a fibreglass non-stretch tape measure fitted with 
a tensioning device (Gulick II Tape Measure, Fitness 
Mart USA). Seated blood pressure will be measured in 
triplicate with 1 min between each measure. All physical 
measures are performed by assessors trained according to 
the study manual of procedures.
Fasting blood sample
A fasting venous blood sample will be collected (to be 
analysed for glucose, insulin, HbA1c, HDL and LDL 
cholesterol, triglycerides). When baseline/enrolment 
appointments are scheduled at times when it may be 
inappropriate to fast, participants will be asked to arrange 
for a fasting blood sample to be collected at an alterna-
tive appointment within 7 days of the enrolment visit and 
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Questionnaires
Participants will be provided with a questionnaire booklet 
which they will be asked to complete and return to the 
trial team in a postage paid envelope provided. The ques-
tionnaire booklet contains the following measures:
 ► OWLQOL: a weight-specific instrument intended to be 
used to assess obesity-specific symptoms and quality of 
life, general functional status and well-being, and per-
son-specific preference measurement.21
 ► Quality of life: EQ-5D will be used as a standardised val-
idated instrument used for measuring general health 
status.22
 ► Programme adherence: self-reported adherence to the 
allocated programme and methods participants are 
using to attempt to lose weight will be recorded by 
questionnaire.
 ► Programme feedback: will be assessed using several 
5-point Likert scales, including whether there is an 
aim to continue with the programme.
 ► OxFAB: a questionnaire to assess personal strategies 
used by individuals for the purposes of weight loss.18
Retention and withdrawal
We will seek to follow up all participants except those 
who expressly withdraw from the study. Participants who 
decide to withdraw from or discontinue the intervention 
allocated as part of the study will be asked to return for 
follow-up visits to collect outcome measures. To promote 
participant retention and complete follow-up, partici-
pants will be offered a £10 gift card for attending each of 
the 6-month and 12-month follow-up visits.
Adverse events
AEs are of relevance in this trial because many prac-
titioners feel these programmes are poorly tolerated 
and unsuitable for routine use in primary care. We will 
record AEs following Good Clinical Practice. All serious 
and non-serious AEs that occur during the first 12 weeks 
of the study or until the termination of the weight loss 
programme will be recorded in participants who initiate 
one of the weight loss interventions. We will also record 
all AEs that are presumed to be or known to be related to 
gallstones up to 6 months.
data management
Data will be recorded in a web-based data capture system 
(OpenClinica), which is hosted by the Primary Care Clin-
ical Trials Unit of the University of Oxford. This system 
is customised and has an audit trail facility. Ranges and 
programmed validation checks are implemented in the 
system in order to aid reliable data entry.
statistical analysis
The primary and secondary outcomes will be assessed 
using an intention-to-treat analysis by an independent 
statistician. Each continuous outcome will be assumed to 
follow the normal distribution and be analysed by means 
of a linear mixed-effects model, adjusted for outcome at 
baseline. The model will include fixed-effects terms for 
randomised group, visit, interaction between randomised 
group and visit, and baseline BMI (for non-weight 
outcomes only), and random effects to account for 
repeated measures on the same participant at 3, 6 and 
12 months. No adjustment will be made for baseline BMI 
in the analysis of the weight outcomes due to its strong 
collinearity with baseline weight. A random effect will 
also be included for individual practice. An unstructured 
variance–covariance matrix will be specified between 
repeated measurements on the same individual, and the 
random effects for patient and practice will be assumed to 
be independent. The adjusted treatment effect together 
with the 95% CI and p value will be reported. The analysis 
will be performed using PROC MIXED in SAS Version 
9.4. The proportion of participants who lose 5% and 
10% of their initial weight at 12 months, respectively, 
will be presented, and the adjusted difference between 
the two arms and 95% CI will be reported. The binary 
outcome will be analysed by means of a logistic mixed-ef-
fects model, adjusting for baseline BMI (fixed effect) and 
practice (random effect). The number needed to treat to 
achieve 5% or 10% weight loss, defined as the inverse of 
the absolute difference in proportions, will be reported 
if the differences between the treatment and control 
groups are statistically significant. A full statistical analysis 
plan will be prepared prior to any data analysis.
Qualitative substudy
The purpose of this study is to examine participants’ views 
of the programmes. In particular, we aim to examine 
the features that helped or hindered adherence to the 
programme and participants’ views of the behavioural 
support provided in the respective programmes. We will 
therefore purposively sample participants based on their 
responses to the satisfaction questionnaire, reflecting posi-
tive, neutral and negative evaluations. Where possible, we 
will select participants to reflect both genders, socioeco-
nomic status and ethnic group differences. We anticipate 
interviewing around 20 participants in the intervention 
group and 10 in the control group, but sampling will 
continue until saturation is reached, evidenced by no new 
themes occurring.
We will develop a semistructured topic guide for the 
interviews. The interviewer will encourage respondents to 
discuss their perceptions and experiences freely and in 
depth. The interview will set the context by asking about 
previous experience of weight management. Thereafter, 
we will ask for participants’ views on which component 
parts of their treatment they felt were effective and 
which they felt were not effective; thoughts about ability 
to continue to manage their weight when treatment has 
ended; and their views on medication adjustments where 
these occurred. The acceptability of the weight manage-
ment treatment programmes and any preference they 
initially had for the total diet replacement programme or 
the usual care programme will be explored.
Data from participants will be collected in a confiden-
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All interviews will be transcribed. To examine saturation, 
analysis will proceed concurrently with interviewing.
trial steering committee
An independent Trial Steering Committee (TSC) will 
provide oversight of all matters relating to participant 
safety and data quality and value to the public. Due to 
the low risk nature of the DROPLET trial and that it is 
an open-label trial, the TSC also has the role of the Data 
Monitoring Committee, in addition to its role as the TSC. 
However, there are no early stopping rules, and all AEs 
are evaluated unblinded to allocation by the trial manage-
ment group as well as the TSC.
The TSC includes an independent clinician, dietitian, 
statistician and two patient representatives. The TSC has 
reviewed the trial protocol, statistical analysis plan and the 
suitability of the proposed safety data to be collected. No 
interim analysis is planned for this trial due to the short 
recruitment period and low risk nature of the two dietary 
approaches.11 The trial may be subject to inspection and 
audit by the University of Oxford, under their remit as 
sponsor, the trial coordinating centre as the Sponsor’s 
delegate and other regulatory bodies.
Ethics and dissemination
The study protocol (V.4.0; 5 October 2016) was reviewed 
and approved by the South Central Oxford B REC 
Committee (Ref: 157/SC/0337). Any protocol modi-
fications will be sent for review by the research ethics 
committee and will be amended at the trial registry.
It is planned that results will be disseminated to 
academic and health professional audiences via presen-
tations at conferences and publication in peer-reviewed 
journals. Participants will be sent a summary of the trial 
findings at the time when the main article is published. If 
the trial shows this intervention is effective, the results will 
be communicated to policymakers and commissioners 
of weight management services through briefing papers 
summarising the main findings. We will also provide the 
results to all participants coincident with publication 
and disseminate the results to the public through a press 
release, regardless of what the results show.
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